{"name":"Vera Therapeutics","slug":"vera","ticker":"VERA","exchange":"NASDAQ","domain":"veratx.com","description":"Vera Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for nephrology-related diseases. The company's pipeline includes several promising candidates, including its lead product, VTX-801, which is currently in Phase 3 clinical trials. With a strong focus on kidney disease, Vera Therapeutics is well-positioned to capitalize on the growing demand for nephrology treatments. As a clinical-stage biotech, Vera Therapeutics is still in the early stages of development, but its pipeline and focus on nephrology make it an exciting company to watch.","hq":"Brisbane, CA","founded":0,"employees":"","ceo":"Marshall Bhatt","sector":"Clinical-Stage Nephrology Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$3.8B","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":215256000,"netIncome":-299615000,"cash":354725000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"VTX-801 patent cliff ($0.0B at risk)","drug":"VTX-801","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"FDA Grants Fast Track Designation to VTX-801 for Primary Hyperoxaluria Type 1","summary":"The FDA has granted Fast Track designation to VTX-801, Vera Therapeutics' lead product, for the treatment of primary hyperoxaluria type 1.","drugName":"VTX-801","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Vera Therapeutics Reports Third Quarter 2023 Financial Results","summary":"Vera Therapeutics reported its third quarter 2023 financial results, with a net loss of $23.4 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQMTZ4LUR0bWx2MWFiR2IzUkluLTNzLXhSM0pSSVRpVzY0djZGZmVuWlZaODE3OV8tYnVUcnBQZXNSUmFLUVBoUG5FMEpIby1HNlo3aXh5Y0RyVUFfNnlNa0Z0em9CVmNCb0JKd3IyakJVX0duWGI3Y1FVWTdlWFB4dkszdlg2dGVnT2RzZ3ZlSjZXZXExMXdrSzUzd3F6b3hBNWtnOWt2UVpGMGp1TW45MG12bEMzb3ZI?oc=5","date":"2026-03-25","type":"pipeline","source":"Stock Titan","summary":"Biotech nearing drug launch hires veteran lawyer as legal chief - Stock Titan","headline":"Biotech nearing drug launch hires veteran lawyer as legal chief","sentiment":"neutral"},{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNZTdlZEtCMXhDRmxGYmRuWXR2V1JndVgyUUhmZzk0c3VleldjenpmYWcwaDNXOTY0VElhTUN5X09fbFV2bXhkYnZFWkJ1aXR6ZXo4UnFYV21RdDRDTEFnQVE3YWFzdW9oQ3JJdzF2OG1hNEI4LWRBanpYbG1qMGwyM011Vm5iR0RwQmRrT0c2NVc0clIwOEZEZXFGN2RrRXc?oc=5","date":"2026-03-05","type":"pipeline","source":"Quiver Quantitative","summary":"Vera Therapeutics Appoints Christopher Hite to Board of Directors - Quiver Quantitative","headline":"Vera Therapeutics Appoints Christopher Hite to Board of Directors","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-05","type":"pipeline","source":"The Manila Times","summary":"Vera Therapeutics Appoints Christopher Hite to Board of Directors - The Manila Times","headline":"Vera Therapeutics Appoints Christopher Hite to Board of Directors","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNYUtxLXh4ck9oYUNsVkZLUTNTRWJYdXJZdl9iR2g5OHpqUWZUUmU2WHA3Q25EdDR2aGhBd3FRcU9JVWRjb3hIRzVKRlhTeWg4bjg2UV8xYUxBQU1uWXQ3YTJJbEtsSVZDdW01b0Ezb1FzSXJSdnVSek01N3EycktHTXR1bzBRREdQd2dINGxjS2JxdXdp?oc=5","date":"2026-01-07","type":"pipeline","source":"The Motley Fool","summary":"Why Vera Therapeutics Stock Zoomed Higher Today - The Motley Fool","headline":"Why Vera Therapeutics Stock Zoomed Higher Today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxOZVQ2OUt4OVlvVDVHWVBhMU1hRllaU21nT1VZWmEyR2d1N0NDWS1iSnNwZXljaXczYW9SWUdqbTVobUhBUDlrU1pTTElCb09OWXRyeTVsQTExZFEyMHA2MDhMQm0yUGJ2QlduQVlfRlZ4OWZkUUpHWUk0TWVmRF9iU28xX0xzTzdBaWZacXlxQmdLN21NYlVXQjZtTmpSc2dQMWFBcS1WRHF0V05ReHcxNFhld0RjOVJxa05xaUY4UHNPYVl3Y0w2ZDVod1pENFZERUlFTQ?oc=5","date":"2025-12-11","type":"pipeline","source":"TechStock²","summary":"Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets - TechStock²","headline":"Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOUUNuWDgyTzNkOUpMR2NiUlNYQy1IT3N1WmVCMDRMUXpiMGN6c3N5Y2FNY1FheXc0aThoMV9IS1RUZzJwSHI2UzBRb1ItT1ZZS1NISnUxV3FZTExvVUFESkNFSnpyTVl3ZW5Ja3huWUxSNjMtMkF4OXNIVjJVeUg3SDRNdlZ0bGgxSUZBWmw1SkVqQjhIN2tYNFRaQXNCQXludlB3ZzhBdFBrZVJReUpocUhsMEVnUEF2WE03RQ?oc=5","date":"2025-12-03","type":"regulatory","source":"Seeking Alpha","summary":"Vera Therapeutics: Stock Rises As IgAN Approval Chances Increase - I'm On Sidelines (VERA) - Seeking Alpha","headline":"Vera Therapeutics: Stock Rises As IgAN Approval Chances Increase - I'm On Sidelines (VERA)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPNmJqR1UzNlVIRzJzdXAzUVl3bDRMZ3VOSFJnZ2JTNkplZnczWi1wYWlTUVhtM3FiQkxiVDI3WTBQSjQ4SnhDblZ3dlZldDZjMEZTMGNXRHk4dEVjVUQ2Q2JBb0l3ZkFhQmJUVzlfQTVJMlNFQVlQOFpsMndiQVA3TGtrZ2JsZjBvZGhXaFNfY1hqcDFTVHhYTQ?oc=5","date":"2025-12-02","type":"pipeline","source":"The Motley Fool","summary":"Why Vera Therapeutics Stock Rocked the Market on Tuesday - The Motley Fool","headline":"Why Vera Therapeutics Stock Rocked the Market on Tuesday","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNSTFEVTNJbW1kNzBJYTU1bDUzMkNKb1NtSWhEZXRoQVRCU3hIQ0txcGRuS2FQQXJRLUFxQURnU2J4VDVwYU9vSWJyM2NrblFaeU5qTFYtMmlyRnJTLWVBelpCeDlVUVZYTHdaXzNjeWw4ZklzemdaQmRFTVgwdjQ0TmM3Y1pNLVE3SXhwTFZNTGp4M3ZoNTBfcnhNa0Q0YlBRVGxFdTUtOHZxS3pSZUE?oc=5","date":"2025-11-26","type":"pipeline","source":"The Business Journals","summary":"After pivot, this Bay Area CEO says company is hiring and 'almost to the starting line' - The Business Journals","headline":"After pivot, this Bay Area CEO says company is hiring and 'almost to the starting line'","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE5XR3pORXBvRDNucVo3TUxVeHlaQ0lnTTBJYWRrTkgtRmJEdzZEeEo2bGRqTmdTSkV0eE1uVGVpd0Rla09mdXVFS2V4ekJQY05fV1Mwd0NDZWZua04yMHdDZmdvNm5odFpwUG9sOFNkNUQ4dDhG?oc=5","date":"2025-06-06","type":"pipeline","source":"Barron's","summary":"Biotech Stock Vera Is Slumping After Monster Gain - Barron's","headline":"Biotech Stock Vera Is Slumping After Monster Gain - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQMy05OHJEYVAzbUpXZ0toRWhsM0VaMWVLN3paOTQ5dVlIYXpPRWJwYU8yZGVwRVhrTDk3Rkk1ZURCc0Z2TjZxYlVuc3o4VTBYQ01ua3NISXh5b3ZDVGEtaHlGREhTUWRsLXlSLTc3RFF6ZENIR1ZkS1VIWFNlRjlJal90MWpKeWtocElyZlVRUTE4RVpI?oc=5","date":"2025-06-02","type":"trial","source":"statnews.com","summary":"Vera Therapeutics reports positive results from trial of kidney disease drug - statnews.com","headline":"Vera Therapeutics reports positive results from trial of kidney disease drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNQUQ2VThLRmdZaS1zQlZweEJ1WWR6bFBBMmdmLV9xV0pDYWU1eDdaYzZmY0UyWHJSUHU4YXRvQzlmcTREWEcwaEE1TnYzOHZqcWZTbEpmYnVNX3lWWlFubkh0VHAtWmVkYmJCQzJBaThrVmRlVk51MUFBMzJrMi1pelJmSjg0eS1jakxxMGFxd0RYNG0tVEFxZlVR?oc=5","date":"2025-06-02","type":"trial","source":"BioPharma Dive","summary":"Vera drug scores in closely watched study in rare kidney disease - BioPharma Dive","headline":"Vera drug scores in closely watched study in rare kidney disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5QUER1MGlENU5lWkhOZ0dsUU9NRWNWVEhNemgycXlKbU84cnVkZDRHak9BQ2FJRUpMakRUSmo0NWhWQ2t4aXB2Qi1jb01EZHk4YTR3?oc=5","date":"2025-06-02","type":"regulatory","source":"firstwordpharma.com","summary":"Vera delivers IgAN win, but clock favours Otsuka in regulatory race - firstwordpharma.com","headline":"Vera delivers IgAN win, but clock favours Otsuka in regulatory race","sentiment":"neutral"}],"patents":[{"drugName":"VTX-801","drugSlug":"asfotase-alfa","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Alexion Pharmaceuticals","Sanofi","AstraZeneca"],"therapeuticFocus":["Nephrology","Kidney Disease"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":215256000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-299615000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":354725000,"cashHistory":[],"totalAssets":734733000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}